June 10th to 13th, 2015, the annual conference of the European League Against Rheumatism will take place in Rome. Because of this year’s collaboration with the Paediatric Rheumatology European Society (PReS), part of the programme will focus on rheumatic diseases in children. With an expected 14,000 participants from 120 countries, the EULAR congress 2015 promises to become a major international event.
According to Professor Maurizio Cutolo, president of EULAR, topics to look out for are the upcoming biosimilar drugs, new treatments for psoriatic arthritis and the emerging role of epigenetics in rheumatic diseases. Furthermore, there will be a variety of sessions: from Basic and Translational Science, Clinical Science and Challenges in Clinical Practice to Practical Skills, What Is New (WIN) and How to Treat (HOT) sessions. “Altogether, almost 180 sessions are planned with more than 500 speakers and 35 symposia. The poster area – in our view the heart of a modern congress – will host more than 2,000 presentations and will be accessible throughout the entire day”, Cutolo states in EULAR Congress News.
All presentations will be recorded and made available for
attendants at the EULAR website.
Another way to stay up-to-date is the MedZine app, which filters more than 4,700 medical news sources and selects the articles that are relevant for your profession. All news about EULAR can be found under ‘Rheumatology Other’.
See our summary below for some of the highlights of EULAR Congress 2015:
Wednesday, June 10th, a special PReS session will cover the transition from paediatric and adult care from 5:00 to 6:30 PM. In practice, “this is often poorly managed and could have adverse consequences for health and loss to follow-up”, says Tadej Avcin, Professor in Paediatrics at the University Children’s Hospital in Ljubljana, Slovenia, in EULAR Congress News.
On Thursday, June 11th, the Basic and Translational Science session from 3:45 to 5:15 PM will be all about imaging. Dr. Maya Buch, chair of the EULAR Scientific Programme Committee, explains the session will discuss “state-of-the-art imaging to understand pathophysiology and disease mechanisms, particularly focussing on the examination of lymph node stromal cells, to understand the dynamics of the immune system in the context of immunological tolerance.”
Friday, June 12th, will bring a Clinical Science session on combination therapy with biologics in rheumatic disease from 3:45 to 5:15 PM. “This session explores the opportunities of emergent drug technology with talks on bispecific antibodies, which combine the functionality of two antibodies in one molecule in order to enhance immunotherapeutic potential, and fusion proteins, that can combine anti-cytokine and analgesic effects”, Dr. Buch says.
Saturday, June 13th, the last day of the EULAR Congress, will focus on comorbidities during the Clinical Science session from 8:30 to 10:00 AM, followed by Challenges in Clinical Practice from 12:00 to 1:30 PM, where several difficult cases of poly-autoimmune diseases will be discussed.